Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.44 |
| ▸ | CCND1 | P24385 | 1/20 | 0.44 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30078035 | 0.85 | GCK (0.46) | HTTLMNABRD4 | |
| SCHEMBL15066327 | 0.85 | RXRA (0.53) | MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL15065590 | 0.85 | GCK (0.46) | HTTLMNABRD4 | |
| SCHEMBL30078118 | 0.85 | RXRA (0.53) | MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL15065063 | 0.83 | MRGPRX4 (0.59) | — | |
| SCHEMBL30078087 | 0.83 | MRGPRX4 (0.59) | — | |
| SCHEMBL6381048 | 0.82 | L3MBTL1 (0.45) | MAPTL3MBTL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL6381052 | 0.82 | L3MBTL1 (0.45) | MAPTL3MBTL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL24228010 | 0.82 | SMN1; SMN2 (0.51) | MAPTL3MBTL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL30077975 | 0.82 | SMN1; SMN2 (0.44) | MAPTL3MBTL1SMN1; SMN2STAT3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021253091-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2021-12-23 | — | — | WO | disclosed |
| US-11155547-B1 | Compounds for and methods of treating diseases | Alterity Therapeutics Limited (AU) | 2021-10-26 | — | — | US | disclosed |
| US-20090312313-A1 | COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-12-17 | — | — | US | disclosed |
| US-7560558-B2 | Compound having TGFβ inhibitory activity and medicinal composition containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-07-14 | — | — | US | disclosed |
| US-7528149-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-05 | — | — | US | disclosed |
| CN-100334085-C | Quinuclidine compound and medicine containing the same as active ingredient | EISAI R & D CO LTD (JP) | 2007-08-29 | — | — | CN | disclosed |
| US-20070135404-A1 | Respiratory Syncytial Virus Replication Inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-06-14 | — | — | US | disclosed |
| US-7179811-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-20 | — | — | US | disclosed |
| US-20070015747-A1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA, N.V. | 2007-01-18 | — | — | US | disclosed |
| US-20060111375-A1 | Compound having tgfß inhibitory activity and medicinal composition containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-05-25 | — | — | US | disclosed |
| EP-1217001-B1 | QUINUCLIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | EISAI CO LTD (JP) | 2005-12-07 | — | — | EP | disclosed |
| CN-1688549-A | Compound having TGF-beta inhibitory activity and medicinal composition containing the same | KIRIN BREWERY (JP) | 2005-10-26 | — | — | CN | disclosed |
| EP-1548008-A1 | COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-06-29 | — | — | EP | disclosed |
| US-6747028-B1 | 1,2-SUBSTITUTED BENZIMIDAZOLES HAVING ANTIVIRAL ACTIVITY | HANSSEN PHARMACEUTICA, N.V. (BE) | 2004-06-08 | — | — | US | disclosed |
| EP-1196409-B1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2004-02-04 | — | — | EP | disclosed |
| US-6599917-B1 | A squalene-synthesizing enzyme inhibitor, a cholesterol biosynthesis inhibitor and a triglyceride biosynthesis inhibitor | EISAI CO., LTD. (JP) | 2003-07-29 | — | — | US | disclosed |
| CN-1377349-A | Quinuclidine compound and medicine containing the same as active ingredient | EISAI CO LTD (JP) | 2002-10-30 | — | — | CN | disclosed |
| EP-1217001-A1 | QUINUCLIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Eisai Co., Ltd. (JP) | 2002-06-26 | — | — | EP | disclosed |
| EP-1196409-A2 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001000612-A2 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111375-A1 | Compound having tgfß inhibitory activity and medicinal composition containing the same | TGFB1, TGFBR1, TGFBR2 | MAPT 2587/4885L3MBTL1 3960/4885SMN1; SMN2 3891/4885 |
| US-11155547-B1 | Compounds for and methods of treating diseases | HTT, SNCA, PARK7 | MAPT 6/4885L3MBTL1 2678/4885SMN1; SMN2 10/4885 |
| US-20070135404-A1 | Respiratory Syncytial Virus Replication Inhibitors | SARS1, ACE, MAVS | MAPT 4749/4885L3MBTL1 3155/4885SMN1; SMN2 1830/4885 |
| US-20090312313-A1 | COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | TGFB1, TGFBR1, TGFBR2 | MAPT 2545/4885L3MBTL1 4449/4885SMN1; SMN2 3772/4885 |
| US-20070015747-A1 | RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS | SARS1, ACE, MAVS | MAPT 4749/4885L3MBTL1 3155/4885SMN1; SMN2 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.